January 2023

31 Jan 2023 GPN Vaccines Closes AUD$9 million (USD$6 million) Series A3 Investment Round

Posted at 09:09h in Announcements

Adelaide, Australia, 31^st January 2023 - GPN Vaccines is pleased to announce the closing of its Series A3 investment round, raising AUD$9 million (USD$6 million).

16 Jan 2023 First Participant Dosed in Phase 1 Clinical Trial of Gamma-PN Vaccine

Posted at 10:51h in Announcements

Adelaide, Australia, 16th January 2023 GPN Vaccines Ltd is pleased to announce that the first participant has been dosed in its Phase 1 clinical trial of Gamma-PN vaccine in healthy volunteers. The Phase 1 clinical trial will assess the safety, tolerability and immunogenicity of Gamma-PN. One hundred...

Protecting children and adults from the world’s foremost bacterial pathogen

January 2023

31 Jan 2023 GPN Vaccines Closes AUD$9 million (USD$6 million) Series A3 Investment Round

16 Jan 2023 First Participant Dosed in Phase 1 Clinical Trial of Gamma-PN Vaccine

Meet us at

Follow us on social media

Subscribe Here